Arcus Biosciences Inc. (RCUS)
NYSE NYSE Primary Summary
Wall Street Analysts See a 57.56% Upside in Arcus Biosciences (RCUS): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 57.6% in Arcus Biosciences (RCUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Arcus Biosciences, Inc. (RCUS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Arcus Biosciences, Inc. (RCUS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
RCUS Stock Down on Decision to Discontinue GILD Partnered Study
Arcus halts the late-stage STAR-221 study for futility, dealing a setback to its domvanalimab program with Gilead. Stock down.
Arcus Biosciences Inc. (RCUS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Arcus Biosciences Inc. ever had a stock split?
Arcus Biosciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | Terry J. Rosen CEO | NYSE Exchange | 03969F109 CUSIP |
| US Country | 627 Employees | - Last Dividend | - Last Split | 15 Mar 2018 IPO Date |
Overview
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focusing on the development and commercialization of innovative cancer therapies. Founded in 2015, the company has swiftly advanced in the biopharmaceutical industry, primarily within the United States. Arcus Biosciences leverages its scientific expertise to create a pipeline of potential therapies aimed at various cancers. Besides oncology, it extends its research into treatments for inflammatory diseases through strategic collaborations.
Products and Services
- Domvanalimab (Anti-TIGIT antibody): This is an anti-TIGIT monoclonal antibody undergoing Phase 2 and Phase 3 clinical trials. Domvanalimab targets the TIGIT receptor, a checkpoint inhibitor that plays a crucial role in the immune response to cancer.
- AB308 (Anti-TIGIT Monoclonal Antibody): Similar to Domvanalimab, AB308 is an investigational treatment but is in the earlier Phase 1b clinical trial stage. This therapy focuses on people with advanced solid tumors and hematologic malignancies.
- Etrumadenant (A2a/A2b Adenosine Receptor Antagonist): Currently in Phase 2 clinical trials, Etrumadenant targets A2a and A2b adenosine receptors to potentially disrupt cancer's ability to evade the immune system.
- Quemliclustat (CD73 Inhibitor): This small-molecule inhibitor targets CD73 and is in Phase 1b and Phase 2 clinical trials. By inhibiting CD73, Quemliclustat aims to prevent the conversion of AMP to immunosuppressive adenosine in the tumor microenvironment.
- Zimberelimab (Anti-PD-1 Antibody): An anti-PD-1 antibody, Zimberelimab is being studied in Phase 2 clinical trials for its effectiveness in treating metastatic cell lung cancer and as a monotherapy.
- AB521 (Oral Small Molecule HIF-2a Inhibitor): This is in Phase 1 clinical trials and focuses on treating Von Hippel-Lindau disease, a genetic disorder that can cause tumors and cysts in different parts of the body.
- Preclinical Pipeline Products: The company is also developing AB598, a CD39 antibody aimed at inhibiting an enzyme involved in the suppression of immune responses against tumors, and AB801, a small molecule Axl inhibitor, which is thought to play a role in cancer cell survival and metastasis.
In addition to these products, Arcus Biosciences has established collaborative efforts, such as with AstraZeneca to evaluate the combination of domvanalimab and durvalumab in a Phase 3 clinical trial for unresectable Stage 3 non-small cell lung cancer (NSCLC), and with BVF Partners L.P. to discover and develop treatments for inflammatory diseases.
